What type of study is this?

This is a Narrative Review study.

September 10, 2025Archiv EuromedicaOpen Access

Therapeutic Progress in Non-Small Cell Lung Cancer (NSCLC): Molecular Targets and Immunotherapy

View Full Paper

Ask AI

Bookmark

Authors

Narrative review highlights molecular targets and immunotherapy effectiveness in non-small cell lung cancer, indicating therapeutic progress.

New therapies targeting EGFR and other molecular targets show promise, but their clinical significance needs clarification.
Combination treatments are yielding statistical improvements in survival outcomes, especially in resistant cases of lung cancer.
Molecular profiling allows for personalized treatment approaches in managing non-small cell lung cancer effectively.
Emerging immune-based strategies like CAR-T cells and bispecific antibodies are expanding therapeutic options for NSCLC.

Krawczyk et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Narrative review highlights molecular targets and immunotherapy effectiveness in non-small cell lung cancer, indicating therapeutic progress.